167 related articles for article (PubMed ID: 26068014)
1. The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment.
Espelund U; Grønbæk H; Villadsen GE; Simonsen K; Vestergaard PF; Jørgensen JO; Flyvbjerg A; Vilstrup H; Frystyk J
Growth Horm IGF Res; 2015 Aug; 25(4):174-81. PubMed ID: 26068014
[TBL] [Abstract][Full Text] [Related]
2. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma.
Dong ZZ; Yao DF; Yao DB; Wu XH; Wu W; Qiu LW; Jiang DR; Zhu JH; Meng XY
World J Gastroenterol; 2005 Aug; 11(30):4655-60. PubMed ID: 16094705
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.
Abou-Alfa GK; Capanu M; O'Reilly EM; Ma J; Chou JF; Gansukh B; Shia J; Kalin M; Katz S; Abad L; Reidy-Lagunes DL; Kelsen DP; Chen HX; Saltz LB
J Hepatol; 2014 Feb; 60(2):319-24. PubMed ID: 24045151
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?
Morace C; Cucunato M; Bellerone R; De Caro G; Crinò S; Fortiguerra A; Spadaro F; Zirilli A; Alibrandi A; Consolo P; Luigiano C; Resta ML; Ferraù O; Spadaro A
Eur J Intern Med; 2012 Sep; 23(6):e157-61. PubMed ID: 22863442
[TBL] [Abstract][Full Text] [Related]
5. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation.
Huynh H; Chow PK; Ooi LL; Soo KC
Cell Growth Differ; 2002 Mar; 13(3):115-22. PubMed ID: 11959812
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor-1 and expression of its binding protein‑3 in chronic hepatitis C and hepatocellular carcinoma.
Adamek A; Kasprzak A; Mikoś H; Przybyszewska W; Seraszek-Jaros A; Czajka A; Sterzyńska K; Mozer-Lisewska I
Oncol Rep; 2013 Sep; 30(3):1337-45. PubMed ID: 23784592
[TBL] [Abstract][Full Text] [Related]
7. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study.
Chun YS; Huang M; Rink L; Von Mehren M
World J Surg Oncol; 2014 Jul; 12():231. PubMed ID: 25052889
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel assay for IGFBP-2 complexed with IGF-I and-II in human serum.
Agerholm J; Hjortebjerg R; Espelund U; Rasmussen TR; Folkersen B; Bjerre M; Frystyk J
Growth Horm IGF Res; 2020 Apr; 51():38-45. PubMed ID: 32035328
[TBL] [Abstract][Full Text] [Related]
10. Association of elevated IGFBP-1 with increased IGF-II concentration in patients with carcinoma of the liver.
Nedic O; Malenkovic V; Dukanovic B; Baricevic I
Int J Biol Markers; 2008; 23(4):225-30. PubMed ID: 19199270
[TBL] [Abstract][Full Text] [Related]
11. Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells.
Ji Y; Wang Z; Chen H; Zhang L; Zhuo F; Yang Q
Cell Physiol Biochem; 2018; 47(1):39-53. PubMed ID: 29763915
[TBL] [Abstract][Full Text] [Related]
12. Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma.
Mattera D; Capuano G; Colao A; Pivonello R; Manguso F; Puzziello A; D'Agostino L
Clin Endocrinol (Oxf); 2003 Dec; 59(6):699-706. PubMed ID: 14974910
[TBL] [Abstract][Full Text] [Related]
13. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum.
Jeyaratnaganthan N; Grønbaek H; Holland-Fischer P; Espelund U; Chen JW; Flyvbjerg A; Vilstrup H; Frystyk J
Clin Endocrinol (Oxf); 2010 May; 72(5):625-32. PubMed ID: 19769623
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma.
Ranke MB; Maier KP; Schweizer R; Stadler B; Schleicher S; Elmlinger MW; Flehmig B
Horm Res; 2003; 60(4):174-80. PubMed ID: 14530605
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis.
Wu YL; Ye J; Zhang S; Zhong J; Xi RP
World J Gastroenterol; 2004 Sep; 10(18):2740-3. PubMed ID: 15309731
[TBL] [Abstract][Full Text] [Related]
16. Effects of parenteral nutrition without and with growth hormone on growth hormone/insulin-like growth factor-1 axis after hepatectomy in hepatocellular carcinoma with liver cirrhosis.
Cao J; Luo SM; Liang L; Lai J
JPEN J Parenter Enteral Nutr; 2007; 31(6):496-501. PubMed ID: 17947606
[TBL] [Abstract][Full Text] [Related]
17. Expression of insulin-like growth factor II in chronic hepatitis B, liver cirrhosis, and hepatocellular carcinoma.
Seo JH; Park BC
Gan To Kagaku Ryoho; 1995 Aug; 22 Suppl 3():292-307. PubMed ID: 7661600
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma.
Tsai JF; Jeng JE; Chuang LY; You HL; Wang LY; Hsieh MY; Chen SC; Chuang WL; Lin ZY; Yu ML; Dai CY
Scand J Gastroenterol; 2005 Jan; 40(1):68-75. PubMed ID: 15841717
[TBL] [Abstract][Full Text] [Related]
19. The IGF axis and hepatocarcinogenesis.
Scharf JG; Dombrowski F; Ramadori G
Mol Pathol; 2001 Jun; 54(3):138-44. PubMed ID: 11376124
[TBL] [Abstract][Full Text] [Related]
20. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma.
Aishima S; Basaki Y; Oda Y; Kuroda Y; Nishihara Y; Taguchi K; Taketomi A; Maehara Y; Hosoi F; Maruyama Y; Fotovati A; Oie S; Ono M; Ueno T; Sata M; Yano H; Kojiro M; Kuwano M; Tsuneyoshi M
Cancer Sci; 2006 Nov; 97(11):1182-90. PubMed ID: 16965600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
